TY - JOUR AU - Lopez-Sanchez, C. AU - Falco, V. AU - Burgos, J. AU - Navarro, J. AU - Martin, M. T. AU - Curran, A. PY - 2015 DA - 2015// TI - Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature JO - Medicine (Baltimore) VL - 94 UR - https://doi.org/10.1097/MD.0000000000000681 DO - 10.1097/MD.0000000000000681 ID - Lopez-Sanchez2015 ER - TY - JOUR AU - Armstrong-James, D. AU - Meintjes, G. AU - Brown, G. D. PY - 2014 DA - 2014// TI - A neglected epidemic: fungal infections in HIV/AIDS JO - Trends Microbiol VL - 22 UR - https://doi.org/10.1016/j.tim.2014.01.001 DO - 10.1016/j.tim.2014.01.001 ID - Armstrong-James2014 ER - TY - STD TI - Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4):57. ID - ref3 ER - TY - JOUR AU - Limper, A. H. AU - Adenis, A. AU - Le, T. AU - Harrison, T. S. PY - 2017 DA - 2017// TI - Fungal infections in HIV/AIDS JO - Lancet Infect Dis VL - 17 UR - https://doi.org/10.1016/S1473-3099(17)30303-1 DO - 10.1016/S1473-3099(17)30303-1 ID - Limper2017 ER - TY - JOUR AU - Thomas, C. F. AU - Limper, A. H. PY - 2004 DA - 2004// TI - Pneumocystis pneumonia JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMra032588 DO - 10.1056/NEJMra032588 ID - Thomas2004 ER - TY - JOUR AU - Thomas, C. F. AU - Limper, A. H. PY - 2007 DA - 2007// TI - Current insights into the biology and pathogenesis of Pneumocystis pneumonia JO - Nat Rev Microbiol VL - 5 UR - https://doi.org/10.1038/nrmicro1621 DO - 10.1038/nrmicro1621 ID - Thomas2007 ER - TY - JOUR AU - Schafer, G. AU - Hoffmann, C. AU - Arasteh, K. AU - Schurmann, D. AU - Stephan, C. AU - Jensen, B. PY - 2019 DA - 2019// TI - Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomised, open-label multicenter study (IDEAL-study) JO - AIDS Res Ther VL - 16 UR - https://doi.org/10.1186/s12981-019-0250-2 DO - 10.1186/s12981-019-0250-2 ID - Schafer2019 ER - TY - JOUR AU - Zolopa, A. AU - Andersen, J. AU - Powderly, W. AU - Sanchez, A. AU - Sanne, I. AU - Suckow, C. PY - 2009 DA - 2009// TI - Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomised strategy trial JO - PLoS One VL - 4 UR - https://doi.org/10.1371/journal.pone.0005575 DO - 10.1371/journal.pone.0005575 ID - Zolopa2009 ER - TY - JOUR AU - Chan, A. W. AU - Tetzlaff, J. M. AU - Gotzsche, P. C. AU - Altman, D. G. AU - Mann, H. AU - Berlin, J. A. PY - 2013 DA - 2013// TI - SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials JO - BMJ VL - 346 UR - https://doi.org/10.1136/bmj.e7586 DO - 10.1136/bmj.e7586 ID - Chan2013 ER - TY - JOUR PY - 2018 DA - 2018// TI - Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention: Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018) JO - Zhonghua nei ke za zhi VL - 57 ID - ref10 ER - TY - STD TI - Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2020. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 10 Jan 2020. UR - http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf ID - ref11 ER - TY - STD TI - Medical Research Platform. http://www.51yyt.org/FrontPage/login.aspx?Inviter=. Accessed 10 May 2020. UR - http://www.51yyt.org/FrontPage/login.aspx?Inviter= ID - ref12 ER - TY - STD TI - U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed 17 May 2020. UR - https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf ID - ref13 ER - TY - STD TI - U.S. Food and Drug Administration. What is a Serious Adverse Event? 2016. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event. Accessed 17 May 2020. UR - https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event ID - ref14 ER - TY - JOUR AU - Shelburne, S. A. AU - Montes, M. AU - Hamill, R. J. PY - 2006 DA - 2006// TI - Immune reconstitution inflammatory syndrome: more answers, more questions JO - J Antimicrob Chemother VL - 57 UR - https://doi.org/10.1093/jac/dki444 DO - 10.1093/jac/dki444 ID - Shelburne2006 ER - TY - JOUR AU - Longley, N. AU - Muzoora, C. AU - Taseera, K. AU - Mwesigye, J. AU - Rwebembera, J. AU - Chakera, A. PY - 2008 DA - 2008// TI - Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda JO - Clin Infect Dis VL - 47 UR - https://doi.org/10.1086/593194 DO - 10.1086/593194 ID - Longley2008 ER - TY - JOUR AU - Manzardo, C. AU - Esteve, A. AU - Ortega, N. AU - Podzamczer, D. AU - Murillas, J. AU - Segura, F. PY - 2013 DA - 2013// TI - Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort JO - Clin Microbiol Infect VL - 19 UR - https://doi.org/10.1111/j.1469-0691.2012.03991.x DO - 10.1111/j.1469-0691.2012.03991.x ID - Manzardo2013 ER -